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Abstract: CD40 is an important tumor necrosis factor receptor (TNFR) family protein for the development of antitumor response
against cancer cells, apart from its role in the regulation of the immune system as a costimulatory molecule. It is broadly expressed on
the surface of immune cells and in diverse cancer types, including breast cancer. Here, we analyzed both CD40/CD40 ligand expression
in breast cancer cells and tissues using public data sets and overall survival analysis in ungrouped breast cancer patients, as well as
in the triple-negative breast cancer subtype. We detected CD40 gene expression along with its 3 different splice variants (variants
1–3), predominantly in the triple-negative subgroup of breast cancer cell lines. The results of the overall survival analysis showed that
high CD40 gene expression, particularly in the triple-negative subgroup of breast cancer patients, is associated with better survival. In
addition to the transcriptional levels of CD40 splice variants, investigation of protein levels of these variants will allow the categorization
of breast cancer cells and reveal their potential as an immunotherapeutic target.
Keywords: CD40, breast cancer, alternative splicing, transcriptional variant, antitumor response

1. Introduction
CD40, a member of the tumor necrosis factor (TNF)
family, is a 48 kDa Type I transmembrane glycoprotein.
It is expressed on the surface of B cells, macrophages,and
dendritic cells, as well as in various cancer cell lines and
tissues including non-small cell lung cancer, ovarian,
urinary bladder cancer, breast melanoma, pancreatic
cancer, colon cancer, and B-lineage malignancies (Ara et al.,
2018; Argiriadi et al., 2019; Piechutta and Berghoff, 2019).
The interaction between CD40 and its ligand, CD40
ligand (CD40LG), orchestrates dendritic cell–T cell
crosstalk, dendritic cell tolerance, and conversion of CD8+T
cell exhaustion (Ara et al., 2018). Agonistic antibodies
against CD40 display T cell dependent antitumor activity,
especially when used in combination with chemotherapy
and immune checkpoint inhibitors (Bonaventura et al.,
2019).
CD40 expression is induced by lipopolysaccharides (LPS)
at the transcriptional level via nuclear factor kappa B (NFκB) and signal transducer and activator of transcription 1
alpha (STAT-1α) in macrophages and microglia (Qin et al.,
2005). Its expression is regulated at the posttranscriptional
level through alternative splicing when different variants are

formed. Only 3 of these variants (variants 1, 2, and 3) can
be converted to a functional CD40 protein. The CD40 Type
1 variant is the longest isoform, whereas the CD40 Type 2
variant is the soluble form of the protein. Type 3 variant
lacking the cysteine-rich subunit-3/4 (CRD-3 and CRD-4)
display low ligand-binding affinity (Tone et al., 2001).
CD40–CD40LG interaction stimulates growth
inhibition in ovarian, bladder, ovarian, squamous epithelial
carcinoma, and cervical cancer cell lines (Tong et al., 2001).
Agonistic anti-CD40 antibodies either directly activate
macrophages, dendritic cells, or B cells, or indirectly activate
them through cytotoxic lymphocytes and natural killer cells
(Baxendale et al., 2005). CD40 pathway activation is linked
with an improved pathologic response to preoperative
trastuzumab-plus-T/FEC chemotherapy in breast tumors
(Bonaventura et al., 2019). It has also been suggested that
IL-2/CD40 or IL-15/CD40 combination therapy may be
more effective than anti-CD40 alone for the advanced
treatment of solid tumors, including renal cell carcinoma
(Piechutta and Berghoff, 2019).
Ligation of the trimeric recombinant protein
(rCD40LG) with CD40 leads to growth inhibition of breast
cancer cells (Slobodova et al., 2011;Gomes et al., 2009).
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Moreover, it has been shown that cytoplasmic expression of
CD40 is correlated with a better prognosis in breast cancer
(Slobodova et al., 2011). Apart from CD40 expression,
membrane CD40LG expression has been rarely detected
in tumor-infiltrating lymphocytes in breast cancer tissues,
supporting their low capacity to inhibit growth of breast
cancer cells via the CD40–CD40LG axis (Tong et al., 2001).
In contrast, its expression is correlated with an unfavorable
patient prognosis in soft tissue sarcomas (Baxendale et al.,
2005; Ottaiano et al., 2004).CD40 has been associated with
a poor prognosis for stages 3 and 4 esophageal squamous
cell carcinoma patients as well (Matsumura et al., 2016).
In this study, we showed the transcriptional variants of
the CD40 gene in different breast cancer cell lines. We also
aimed to analyze its prognostic value and expression with
its cognate ligand molecule, CD40 ligand (CD40LG),via
public databases.
2. Materials and methods
Cell culture:BT-474, HCC-38, MCF-7, MDA-MB-231,
MDA-MB-468, SK-BR-3, T-47D, ZR-75-1 breast cancer
cell lines and MCF-12A healthy mammary epithelial
cell line were cultured in RPMI medium containing
L-glutamine (2 mM), 10% fetal bovine serum (Biological
Industries, Cromwell, CT, USA), penicillin (100 unit/mL)
and streptomycin (100 mg/mL; Biochrom, Cambridge,
UK).Cell culture was also conducted in the presence of
LPS (1 ug/mL, 24h), which is known to induce CD40
expression.
RNA isolation and Reverse transcription-polymerase
chain reaction (RT-PCR):Total RNA was isolated from cells
using RNeasy Mini Kit (QIAGEN, Hilden, Germany).The
RNA samples were treated with DNA-free kit (Ambion,
Waltham, MA, USA). Following RNA isolation, cDNA
was synthesized using RevertAidTM First Strand cDNA
Synthesis Kit (Fermentas, Waltham, MA, USA). Primers
specific for CD40 variants were designed and synthesized
by Iontek (İstanbul, Turkey). We used the following
primer sequences (from 5′ to 3′) for the PCR: Variant 1
human CD40 forward: TGCCCAGTCGGCTTCTTCT,
reverse: AGTCTTGTTTGTGCCTGCCTG;Variant 2
human CD40 forward:TTGGACAAGGTCCCCAGGA,
reverse: GGGGCCTTATTGGTTGGCT; Variant 3
human CD40 forward: AGCAGATTGGTCCCCAGGA,
reverse:GGGGCCTTATTGGTTGGCT. CD40 variant 1–3
expression was investigated using the RT-PCR method.
PCR was initiated by one hold of 95 °C for 10 min, followed
by 35 cycles of 15 s at 95 °C, 55 s at 60 °C for V2 and V3 or
55 s at 61 °C for V1, and 5 s at 72 °C, followed by one hold
of 72 °C for 10 min. b-actin was used as an internal control.
RT-PCR products were separated using 2% agarose gel
electrophoresis.
Analysis of CD40/CD40LG gene expression from the
CCLE and TCGA databases: The RNA-seq expression
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data of the CD40 gene from all of the cancer cell lines
were downloaded and a total of 66 breast cancer cell lines
were selected. To check the correlation between CD40 and
its ligand CD40LG, The Cancer Genome Atlas (TCGA,
Provisional) data obtained from 529 patients with breast
invasive carcinoma were evaluated.
Survival analysis: CD40 and its cognate receptor
CD40L Gwere evaluated with Kaplan–Meier plotter tool
(http://kmplot.com/analysis/index.php)(Gyorffy et al.,
2010). Patient cohorts were divided into high and low
expression groups according to quantile expression of the
CD40 and CD40LG genes.Hazard ratios (HR) with 95%
confidence intervals and log rank P value were calculated.
Statistical analysis: Significant correlations between
CD40 and CD40LG gene expression levels were evaluated
using the Pearson correlation. Statistical significance was
indicated using a P value of 0.05 or less based on a twotailed test. Analyses were performed using GraphPad
Prism version 8.1.1 (GraphPad, San Diego, CA, USA).
3. Results
3.1. High CD40 expression is associated with a good
prognosis in breast cancer
Prognostic value of CD40 gene expression was determined
in breast cancer using the Kaplan–Meier plotter. In 3951
patients with breast cancer, survival analyses showed that
high CD40 mRNA expression was highly associated with
improved overall survival (OS) (hazard ratios of 0.62–0.77,
P =3.4e-11) (Figure 1a). Furthermore, overall survival was
better in the high-expression group vs. the low-expression
group in patients with triple-negative breast cancer, which
is the most aggressive subtype (hazard ratios of 0.41–0.97,
P =0.034) (Figure 1b). Likewise, high CD40LG expression
was associated with better survival in all breast cancer
(hazard ratios of 0.71–0.89, P = 3.9e-05) and triple negative
breast cancer (hazard ratios of 0.32–0.78, P = 0.0018) data
set (Figure 1c and Figure 1d).
3.2. Breast cancer cell lines express CD40 at mRNA levels
Gene expression data for cancer cell lines were downloaded
from the Cancer Cell Line Encyclopedia (CCLE) database
(Barretina et al., 2012) at www.broadinstitute.org/ccle.
RNA-seq analysis of 66 human breast cancer cell lines
derived from the CCLE data setshowed that breast cancer
cells display low CD40 expression (Figure 2a). Data
analysis of these breast cancer cell lines revealed extremely
low CD40LG expression as well (Figure 2b).
On the other hand, it has been shown that CD40 is
significantly correlated with CD40LG gene expression
in 529 patients with invasive carcinoma of the breast
according to the TCGA (Provisional) data set of the
Agilent microarray platform (Pearson correlation: 0.53, P
< 0.05) (Figure 2c).
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Figure 1. Prognostic value of CD40 mRNAexpression determined using the Kaplan–Meier plotter (A–B). a) Survival curves for all
patients with breast cancer (n = 3951). b) Survival curves for patients with triple negative breast cancer (n = 255). HR: Hazard ratio.
Prognostic value of CD40LG mRNA expression determined using the Kaplan–Meier plotter (C–D). c) Survival curves for all patients
with breast cancer (n=3951). D) Survival curves for patients with triple negative breast cancer (n=255).

3.3. Demonstration of CD40 gene expression with its
splice variants
We checked the 3 isoforms, which can be converted to
protein (Figure 3A). CD40 exons that correspond to
protein domains including cysteine-rich domain (CRD)
1–4 are shown in Figure 3b. Three specific primers were
designed to detect splice variants V1–3 (Figure 3b).

Specific PCR amplicons were detected by agarose gel
electrophoresis and β-actin was used as an internal control
(Figure 3c).
In order to show expression of CD40 splice variants,
the levels of gene expressions were examined using
primers designed specific for the variants. Six out of
8 breast cancer cell lines expressed CD40 variant/
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Figure 2. a) RNA-seq data analysis of CD40 mRNA in breast cancer cell lines (n=66). Log-2–transformed RNA-seq read counts for
CD40 gene are shown on the y-axis. b) RNA-seq data analysis of CD40LG mRNA in breast cancer cell lines (n=66). Log-2–transformed
RNA-seq read counts for CD40LG are shown on the y-axis. c) Correlation between CD40 and CD40LG gene expression based on the
TCGA breast cancer data set.
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Figure 3. a) Schematic demonstrations of CD40 splice variants. b)Illustration of exon regions of CD40 splice variants indicated by
boxes, exon–intron sites to which primers designed specifically binds, and CD40 protein domains corresponding to exon regions. c)
Agarose gel images regarding amplicons of CD40 variants (V1=115 bp, V2=130 bp, V3=130 bp). d) Expression of CD40 splice variants
in breast cancer cell lines cultured with or without LPS. C (–) represents negative PCR control; C(+) represents positive PCR control.

variants. There was no expression detected in MCF-7,
MDA-MB-468, and ZR-75-1. All3 CD40 variants were
detected in cell culture conditions with and without LPS
in SK-BR-3, MDA-MB-231, T-47D, and HCC-38 cell

lines. Similarly, MCF-12A normal breast cells showed a
similar transcriptional pattern as these breast cancer cells
for CD40 splice variants. In the BT-474 cell line, CD40
variant 3 was only detected after induction with LPS in
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Figure 3. (Continued).

cell culture. In the absence of LPS, BT-474 cells were
CD40-negative (Figure 3d).
4. Discussion
CD40, one of the best characterized costimulatory
molecules, has contributed to cell-mediated and humoral
immune responses in the immune system(Loskog and
Eliopoulos, 2009). In addition to its function on the
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immune system, coexpression of CD40 and its ligand
CD40L mediates oncogenic effects on immortalized
human epithelial cells in vitro (Baxendale et al., 2005).
Early phase trials regarding CD154 gene transfer have
shown various cellular consequences, including cytokine
production and enhanced Fas-mediated tumor apoptosis,
following CD40 ligation(Weiss et al., 2009;Tong and Stone,
2003).
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CD40 expression exists on the basal part of stratified
squamous epithelium, suggesting its modulatory role
in cell growth and differentiation (Young et al., 1998).
Epithelial CD40 is limited to self-renewing stem cells. In
murine fibroblasts, constitutive CD40 signaling plays a
pivotal role in the transformation of the cells (Esteva et
al., 2007). It has also been detected in different types of
carcinoma cells. However, its ligand CD40LG has barely
been detected in normal and malignant epithelial cells
(Tong et al., 2001; Tong and Stone, 2003). CD40 has
been detected in all compartments, namely membrane,
cytoplasm, and nucleus, in breast cancer (Makhoul et
al., 2018). Although Her-2/neu breast tumors show
significantly higher cytoplasmic expression of CD40
compared to the Luminal A/B type, its expression is higher
on the membrane surface of MDA-MD-231, a highly
aggressive TNBC cell line (Makhoul et al., 2018).
In our CCLE database analysis, CD40LG mRNA
expression was found to be very low. The TCGA data set
indicated that there was a significant positive correlation
between CD40 and CD40LG. According to the data
analysis, breast cancer cell lines (n=66) displayed extremely
low CD40LG expression, indicating that the main source
of CD40LG expression in breast cancer could be immune
cells, most likely on the cell surface of the activated T cells.
CD40 ligation may have opposite effects on cancer cell
survival. Higher CD40 expression has been associated with
a poor prognosis in gastric cancer, esophageal squamous
cell carcinoma, low-grade gliomas, and glioblastoma
(GBM)(Li et al., 2009; Matsumura et al., 2016; Werner et
al., 2019). Additionally, Kaplan–Meier progression-free
survival curves for non-small cell lung cancer patients
with malignant pleural effusion showed that high soluble
CD40 is associated with poor prognosis (HR = 0.4643, P
= 0.045 (Mu et al., 2015). Since soluble CD40 expression
would suppress CD40LG+ T cells and contribute to
immune escape mechanisms (Kim et al., 2015), it is critical
to explore this splice variant in cancer cells.
Overall, the survival analysis that we performed, in
contrast to the studies on solid tumors mentioned earlier,
has shown that high CD40 expression is associated with
good prognosis in triple-negative breast cancer. Similarly,
tumor-associated CD40 expression has a favorable
prognostic effect in renal cell carcinoma and diffuse
large B-cell lymphoma following chemotherapy (Weiss
et al., 2014;Rydstrom et al., 2010). CD40 expression
is accompanied by CD8 T cell infiltration in renal
cell carcinoma, indicating that it may be useful as a
biomarker for patient survival (Weiss et al., 2014). Both
the detection of CD40 expression in triple-negative cells
and the association of high CD40 expression with good
prognosis led us to clarify variant expressions of this gene.
All CD40 splice variants (V1–3) were detected in 3 out of

4 triple-negative breast cancer cell lines. It appears that
CD40 expression and its stimulation in cancer cells could
be dependent on the cancer cell type-specific signaling
pathway and the immune niche within the cancer
microenvironment.
In this study, we aimed to show CD40 splice variants
under normal conditions, as well as in the presence of LPS,
a strong transcriptional inducer of CD40 gene (Dong et
al., 2008). Previous experiments performed on peripheral
blood monocytic cells showed that LPS induction augments
CD40 mRNA and protein. LPS causing IκBα degradation
leads to NF-κB activation. Furthermore, the activation of
NF-κB has been shown to be essential for CD40 expression
stimulated with LPS on human monocytes, as determined
in murine macrophages and microglia (Pearson et al.,
2001; Wu et al., 2009).
As a result of our experimental assays, we detected the
expression of all 3 variants (V1, V2, and V3) in MCF-12A,
MDA-MB-231, SK-BR-3, T-47D, and HCC-38, which
are ER–/PR–cell lines, except T-47D, which is classified as
Luminal A (ER+PR+HER2–) (Yu et al., 2017). On the other
hand, CD40 splice variants were not shown in MCF-7,
MDA-MB-468, and ZR-75-1 cell lines which diverged from
each other. In the earlier study, consistent with our results,
BT-20 was also identified as CD40-positive, while MCF7 and ZR-75-1 were CD40-negative (Esteva et al., 2007).
Treatment with CD40 ligand decreased proliferation of
BT-20 and T-47D cells which are CD40-positive, but did
not change the growth of CD40-negative breast cancer
cell lines, as detected in MCF-7 or ZR-75-1 cells (Esteva
et al., 2007), supporting the idea that CD40–CD40LG
axis modulates proliferation of cancer cells. Interestingly,
the ER+/PR+/HER2+ breast cancer cell line BT-474 does
express Variant 3 in the presence of LPS. High CD40
expression was detected in the cytoplasm of hormonereceptor–positive breast cancer, whereas it was detected
on the surface membrane of triple-negative breast cancer
(Kim et al., 2015; Slobodova et al., 2011). We thought that
the basal expression of V3, which has low ligand binding
capacity, might be quite low in BT-474 and could be
stimulated by LPS.
When the demonstration of CD40 variant expressions
is technically considered, it can be mentioned that not
showing the variants by sequencing and not quantifying the
expression differences of CD40 variants using quantitative
real-time PCR is among the handicaps of the experimental
assay.Therefore, no further quantitative evaluation of
gene expression has been performed due to the absence
of CD40 expression in some of the breast cancer cell lines
and for the purpose of displaying the existence of CD40
variants (V1–3) only.
In conclusion, investigation of CD40 splice variants’
expression among different types of breast cancer cells is
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important for targeting the secreted or full-length form
of CD40 mRNA. Development of antibodies specific for
CD40 splice variants may provide insight into molecular
mechanisms regarding the CD40 signaling pathway.
Additionally, histopathological analysis of breast tumor
biospecimens in terms of different splice variants of CD40
would be informative for determination of potential
targets and discrimination between the soluble and fulllength forms of the protein. Whether or not CD40 variant
expression change occurs after the use of agonistic CD40
antibodies should be taken into consideration. Further

analysis of the genetic structure and functionality of CD40
and CD40LG would allow the development of more useful
prognostic factors and prognostic prediction tools in
breast cancer subtypes.
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